The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
At least 18 years old and has provided informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.
Received and progressed or been intolerant to prior standard therapy (Part 1 Dose Exploration).
Head and neck squamous cell carcinoma.
Any conditions that may affect the ability to take or absorb study drug.
Major surgery within 4 weeks prior to receiving study drug(s).
Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Revolution Medicines, Inc.
Lead sponsor
Summit Therapeutics
Collaborator